The global Arteriovenous Fistula Treatment Market is projected to amass revenue of about USD 1,356.5 million by 2033. The overall market value is expected to be worth USD 765.8 million in 2023. The worldwide adoption of arteriovenous fistula treatment is projected to advance at a CAGR of 5.9% during this forecast period.
In the near future, the market for arteriovenous fistulas is also likely to be boosted by medicines in the clinical pipeline and supportive government efforts. However, risks associated with arteriovenous fistula needles are likely to create a dent in the market share growth.
The clearance given by FDI of Vascugel, an investigational novel medication for the treatment of failed hemodialysis access grafts, for a pivotal phase III trial by Pervasis Therapeutics, Inc. is one such instance. Therefore, these government initiatives and approvals are expected to open up a wide array of arteriovenous fistula treatment market opportunities and a sound foundation for the expansion of this market.
Due to ongoing efforts by leading companies to provide cutting-edge therapies for the treatment of arteriovenous fistula, the market size is expanding rapidly on a global scale. For instance, in April 2013, Shire released the results of a phase II research to determine the effectiveness and safety of SRM003 (Vascugel) in patients with end-stage renal disease and an arteriovenous fistula.
As per the market report by FMI, the arteriovenous fistula treatment methods are in research to come up in the market, and the same is also likely to sway the market.
For doctors to pinpoint the precise size and location of damaged blood arteries, imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) are helpful, catering to the arteriovenous fistula treatment market growth. To effectively treat arteriovenous fistulas, additional surgical procedures are carried out. To reduce blood clotting in the affected locations, as fistulas in the brain and eye are tough to cure, injectable treatment is employed in this instance.
| Report Attributes or Data Points | Details |
|---|---|
| Global Arteriovenous Fistula Treatment Market Valuation in 2022 | USD 731.6 million |
| Estimated Global Market Share in 2023 | USD 765.8 million |
| Forecasted Global Market Size by 2033 | USD 1,356.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 5.9% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 3.8% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The adoption of arteriovenous fistula treatment is growing over the forecast period as the players are coming up with new treatment methods, such as photodynamic therapy, antiangiogenic therapy, and another method of sclerotherapy.
The effective treatment method for a complete cure in an easy way is still under development process, which initiates the players to come up with innovations for the treatment, shaping the market trends.
On the flip side, the lack of awareness regarding arteriovenous fistula treatment hinders the demand for arteriovenous fistula treatment worldwide.
The market for arteriovenous fistula treatment bears a huge potential as the treatment methods are limited, and the population effect is high, directly influencing the market growth.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 37.2% |
| Europe | 27.4% |
Due to the successful measures taken by the USA government to create novel therapies for the arteriovenous fistula problem, North America controls the majority of the global market share, accounting for 37.2% in 2022.
To this, North America has a huge potential as leading pharmaceutical players are placed in that region, positively impacting the overall market over the forecast period.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 33% |
| Germany | 6.5% |
| Japan | 3.9% |
The second-leading market for arteriovenous fistulas is anticipated to be in Europe, with a share of 27.4% in 2022. Arteriovenous fistula incidence is rising, and there is a strong need for medicines to treat them in Europe, which is mostly responsible for the market's expansion in the region during the forecast period.
Europe's market growth has been soaring, attributed to rising awareness of the treatment in the region.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 5.4% |
| China | 9.4% |
| India | 7.7% |
| Australia | 6.8% |
Numerous start-ups have been emerging in various industries, including the arteriovenous fistula treatment solutions, and are bringing about emerging trends in the market.
Example:
To raise the marketing of its FDA-cleared implant that enables patients with end-stage renal disease (ESRD) to more easily access their vascular system for hemodialysis, Vital Access, a start-up, obtained a USD 10 million credit line from Deerfield Management.
The FDA approved the Salt Lake City, Utah-based company's device in 2013.
In 96% of patients with fistulas confirmed to be uncalculatable in the SAVE research, a prospective, pivotal clinical trial in the United States, it was demonstrated that VWING provided dependable fistula access.
In comparison to published rates, its usage in the study was linked to a significantly decreased incidence of access site and systemic infection over the long term.
| Category | By Type |
|---|---|
| Top Segment | Arteriovenous Fistulas |
| Market Share in Percentage | 29.8% |
| Category | By Treatment |
|---|---|
| Top Segment | Transcatheter Embolization |
| Market Share in Percentage | 42.7% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Players in the market are engaging in various organic and inorganic strategies, including mergers & acquisitions, partnerships, product launches, and collaborations, thereby augmenting their market share.
Recent development:
The WavelinQTM 4F EndoAVF System, BD's next-generation technology, provides additional places to establish an AV fistula while leaving open the possibility of creating AV fistulas through regular surgical procedures in the future.
The surgical scar frequently left behind after creating an AV fistula during open surgery is removed with the endovascular technique, carried out through two tiny punctures or incisions.
Patients concerned about AV fistula formation with standard surgery may opt for an endoAVF.
Other Market Participants:
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Treatment Type, Region |
| Regions Covered | North America; Latin America; Asia Pacific; The Middle East and Africa; Europe |
| Key Countries Profiled | Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa |
| Key Companies Profiled | Becton Dickinson & Company; Medtronic; B. Braun Melsungen Ag; Cook Medical; Teleflex Incorporated; Fresenius Medical Care AG & Co. KGaA; NxStage Medical Inc.; Poly Medicure Limited. |
| Customization | Available Upon Request |
The projected revenue of the market by 2033 is USD 1,356.5 million.
The market CAGR for 2033 is projected to be 5.9%.
North America, Europe, and Asia-Pacific are the leading market.
North America holds the largest market share.
North America is growing fast due to the rising prevalence of chronic diseases.
| Estimated Size, 2024 | USD 28.7 billion |
|---|---|
| Projected Size, 2034 | USD 47.3 billion |
| Value-based CAGR (2024 to 2034) | 5.1% |
| Expected Market Value 2023 | USD 26.64 Billion |
|---|---|
| Projected Market Value 2033 | USD 46.82 Billion |
| Growth Rate (2023 to 2033) | CAGR 5.8% |
Explore Therapeutic Device Insights
View Reports
Arteriovenous Fistula Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
